Escherichia coli eradication from the blader urine by amoxicillin-sulbactam. Intrinsic activity of the inhibitor;Erradicación de Escherichia coli de la orina vesical por amoxicilina-sulbactam. Actividad intrínseca del inhibidor

Enfermedades Infecciosas y Microbiologia Clinica

Volumn 19, Issue 5, 2001, Pages 206-210

  Casellas, José Maréa ^a   Visser, Matías ^a   Tomé, Gabriela ^a   Cohen, Hugo ^b   Soutric, Jorge ^c   Arenoso, Hector ^c  

^a Centro de Estudios en Antimicrobianos (CEA)   (Argentina)

^b Hospital Manuel Belgrano   (Argentina)

^c Laboratorios Bagó S A   (Argentina)

Author keywords

Amoxicillin sulbactam; Urine

Indexed keywords

AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; CLAVULANIC ACID; SULBACTAM;

ARTICLE; BACTERIUM ISOLATION; BLADDER; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG URINE LEVEL; ERADICATION THERAPY; ESCHERICHIA COLI; HUMAN; MINIMUM INHIBITORY CONCENTRATION; PRACTICE GUIDELINE; PROTEUS MIRABILIS; RANDOMIZED CONTROLLED TRIAL;

EID: 1642433364     PISSN: 0213005X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0213-005X(01)72614-6     Document Type: Article

References (11)

1. Casellas JM, Arenoso H, Soutric J, Tomé G, Goldberg M. Estudio comparative in vivo e in vitro de tres asociaciones de inhibidores suicidas de betalactamasas con aminopenicilinas. Rev Esp Quimioterap 1993; 6 (4): 289-296.
2. Bantar C, Nicola F, Arenoso H, Galas M, Soria L, Dana D, et al. Pharmacokinetics and Pharmacodynamics of amoxicillin-sulbactam, a novel aminopenicillin-beta-lactamase inhibitor combination against Escherichia coli. Antimicrob. Agents Chemother 1999; 43: 1.503-1.504.
3. Noguchi JK, Gill M. Sulbactam: A beta-lactamase inhibitor. Clin Pharma 1988; 7: 37-51.
4. Wise R, Andrews JM, Bedford KA. Clavulanic acid and CP 45.899 a comparison of their in vitro activity. J Antimicrob Chemother 1980; 6: 197-198.
5. Bantar C, Nicola F, Fernańdez Canigia L, Arenoso H, Soutric J, Montoto M, et al. A pharmacodynamic model to support a 12-hour dosing interval for amoxicillin/sulbactam a novel oral combination, in the treatment of community-acquired lower respiratory tract infections. J Chemother 2000; 12 (3): 223-227.
6. Casellas JM. Conceptos bacteriológicos en el manejo antibacteriano de las infecciones urinarias. En: Garimaldi J, Lubetkin A, eds. Infecciones Urinarias en la infancia. Río Cuarto: Universidad Nacional de Río Cuarto; 1998; 471-472.
7. Casellas JM, Tomé G, Exeni R, Goldberg M, Farinati A. Serum and urinary cefpodxime levels and time killing curves performed in the urine of children presenting urinary tract infections. Pathol Biol (París) 1993; 41: 385-391.
8. Lassen MK, Edberg SC. Measurement of antibiotics in human body fluids: Techniques and significance. En: Lorian V, ed. Antibiotics in Laboratory Medicine. Baltimore (Md): Williams & Wilkins, 1996; 231-295.
9. Casellas JM, Guzmán M, Pinto ME. The Sleeping Giant: Antimicrobial Resistance. Med Clin North Am 1994; 8: 29-45.
10. Guzmán Blanco M Casellas JM, Sader H. Bacterial resistance to antimicrobial agents in Latin America. The giant is awakening. Infect Dis Clin North Am 2000; 14: 67-77.
11. Casellas JM. Antibióticos y antibiogramas en infecciones urinarias pediátricas adquiridas en la comunidad. Rev Latinoam Nefrol Pediatr 2001; 1: 1-21.